Gold Prices Rise as Fed Rate Hike Bets Ease 
What’s the difference between baking powder and baking soda? It’s subtle, but significant 
How to support someone who is grieving: five research-backed strategies 
Time to buy local: war fuel price shocks reveal the folly of a long food supply chain 
Office design isn’t keeping up with post-COVID work styles - here’s what workers really want 
Oil Prices Rise as US-Iran Talks Stall, Inflation Risks Grow 
South Korean Won Leads Asian FX Losses as Dollar Rises 
Oil Prices Rise as Hormuz Reopening Remains Uncertain 
Stuck in a creativity slump at work? Here are some surprising ways to get your spark back 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Yes, government influences wages – but not just in the way you might think 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
Bubs Australia will manufacture and distribute Bubs’ Chinese-label goat milk infant formula in China according to new Chinese standards. under an agreement with Heilongjiang Ubeite Dairy Group (HUG).
The new standards will come into effect in February 2023 .
The “ultra-premium” infant formula has been specially developed for Chinese infants using easily-digestible A2 goat-milk protein, sn2 palmitate (OPO), lactoferrin prebiotics, and nucleotides.
HUG has started submission with the State Administration for Market Regulation (SAMR) to renew its registration in line with China’s new GB standards for exclusive use under the Bubs brand.
According to Kristy Carr, Bubs founder and CEO, they have built strong brand trust and loyalty with Chinese families through marketing and selling Bubs English label infant formula products via the crossborder eCommerce channel, which accounts for around 20 percent of total Chinese infant formula sales.
If approved by SAMR, the formula will give Bubs access to the remaining 80 percent of China’s $25.9 billion infant formula market.
Bubs will also enter into a joint venture agreement, where it will hold a 75 percent interest, with Zhitong Health Technology to distribute its Chinese label goat infant formula products.
Bubs Australia expects to launch its product in the second half of FY23, subject to receiving SAMR approval.
